

Index

A

- active implantable medical devices (AIMDs) 183
 - biological safety 185
 - country-specific requirements 189–192
 - definition 184–194
 - electrical/electromagnetic safety 186
 - general standards 185–194
 - heat 186
 - markings and symbol requirements 187
 - mechanical safety 187
 - MRI imaging/medical treatments risks 186
 - radiofrequency communication 187
 - regulatory approval principles 187–188
 - sterilization and packaging 186
 - surgical technique validation 187
- adverse event (AE)
 - national level reporting (devices) 211–217
- advertising and promotion
 - for devices 216
- Africa and Middle East
 - universal health coverage (UHC) 91
- Africa and Middle East (AME) region
 - HTA implementation 91
 - regulatory organizations in 6–7
- African Medicines Regulatory Harmonization (AMRH) 6
- ALCOA+ 19
- animal rule
 - for device conformity 141
- APEC Life Sciences Innovation Forum (APEC LSIF)
 - IMDRF regional harmonization 4
 - Regulatory Harmonization Steering Committee (RHSC) 5
- Argentina
 - device traceability and tracking 53
 - traceability and code for medicines 52–58
- Asia
 - HTA adoption in 94–112
 - HTA status of selected countries 93

- Asian Harmonization Working Party (AHWP)
 - harmonization efforts 5
 - IMDRF harmonization initiatives 4
- Asian-Pacific Economic Cooperation (APEC) 5
- Association of Southeast Asian Nations (ASEAN)
 - membership of 4
- Association of Southeast Asian Nations Pharmaceutical Product Working Group (ASEAN PPWG) 5
- Australia
 - AIMD requirements 189–194
 - essential principles for IVDs 177–181
 - HTA process for reimbursement 101
 - HTA use in 98–112
 - IVD classification 176
 - IVD clinical trial requirements 176
 - IVD conformity assessment 177–181
 - IVD regulations 176–181
 - Rule 9 special classification 179

B

- biocompatibility
 - device materials 141
- biological safety, AIMDs 185
- Brazil 15
 - AIMD requirements 191
 - device INMETRO certification 20
 - GMP certificate for marketing 21
 - ICH Q7 adoption 15
 - ISO 13485 use 154–156
 - medicinal product serialization 53–58
- budget-impact analysis (BIA) 81

C

- Canada
 - AIMD requirements 191
 - combination products 228–234
 - HTA implementation in 99

- ISO 13485 compliance 153
- IVD regulations 177–181
- mandatory problem reporting for devices 216
- public system reimbursement decision pathway 105
- Canadian Agency for Drugs and Health Technologies (CADTH)
 - drug review process 102
 - elements and recommendations categories 103
 - HTA implementation 99
- Canadian IVD regulations
 - classification 179–181
 - clinical trial requirements 179
 - Medical Device License (MDL) 179
- cell-based medicinal products
 - good manufacturing and distribution practices 15
- CE marking/certificates of compliance for compliance 154
- Central Social Insurance Medical Council (Chuiyko) 98
- certificate of compliance 21
- chemical, physical, and biological properties for devices 115
- chemistry, manufacturing and controls (CMC), TPLC
 - approach 12
- China
 - aligning with IMDRF UDI recommendations 54, 55
 - counterfeit and regulations 54–58
 - enforcement powers in 25
 - ICH Q7 adoption 15
 - serialization of medicinal products 54–58
- China Food and Drug Administration (CFDA), medicinal
 - product serialization 54
- CLIA categorization
 - single laboratory 175
 - US IVD regulation 171–181
- clinical decision support software (CDS) guidance 199
- Clinical Effectiveness (EFF) 83
- combination products 219
 - designation and premarket review 221
 - human factors 234
 - primary mode of action 221–234
 - product categories 223
 - regulatory challenges 220–234
- combination products (Canada)
 - definition 228
 - designation and review 228–234
 - devices with medicinal product 229–234
 - postmarket requirements 229
 - regulatory pathway 228–234
- combination products (EU)
 - ancillary medicinal product 230
 - consultation procedure 231
 - definition 229–234
 - devices administering medicinal products 231, 232
 - human factors 234
 - manufacturing, labeling, final release 234
 - transition to EU MDR 231
- combination products (US)
 - constituent parts 222–234
 - designation and review 223–234
 - development considerations 224–234
 - FDA approved products 222
 - human factors 225–234
 - manufacturing regulations 226–234
 - postmarketing safety reporting 227
 - postmarketing safety reporting (PMSR) 227
- compliance and enforcement (pharmaceutical products) 11
 - advertising and promotion 19–27
 - anti-corruption 20–27
 - electrical, environmental, and wireless device
 - requirements 20–27
 - GMP requirements for 15
 - import alerts/distribution bans 24
 - market authorization requirements 21–27
 - recalls/market withdrawal/stock recovery 25
 - role of professional in 25–27
 - scope of regulations 12–27
 - surveillance 21–27
 - trade 20–27
- conformity assessment
 - IVD devices 163
 - QMS requirements for devices 148
 - stages of 178
- conformity assessment elements
 - Class A Device 120
 - Class B Device 120
 - Class C Device 121
 - Class D Device 121
 - device classification relationship 165
 - IVD devices 161–180
 - quality management system 147
- corrective and/or preventive action (CAPA)
 - IVD premarket requirement 164
- Corrective and preventive action (CAPA)
 - for software 202
- cosmetic products
 - regulatory requirements 3
- Cost and Economic Evaluation (ECO) 83
- cost-based pricing (CbP) model 62
- cost-benefit analysis (CBA) 81
- cost-effectiveness analysis (CEA) 81

cost-minimization analysis 81
 cost-of-illness analysis 81
 cost-utility analysis (CUA) 81
 counterfeit and regulation
 European legal requirements 44–58
 exemptions by indicifical states 47
 international 33
 legal actions for control of 36
 occurrence and prevention of 34–55
 reported substandard/falsified products 51
 rest of the world 50–58
 risk reduction methods/traceability 37
 terminology for 35
 terminology inconsistencies 34
 US legal requirements 36–58
 cybersecurity, for device software 203

D

Danish Centre for HTA (DACEHTA) 82
 debarment 24
 Declaration of Conformity
 device premarket requirements 118
 for IVDs 164
 Table of Contents (ToC) format for RPS 139
 Description and Technical Characteristic of Technology
 (TEC) 83
 design qualification (DQ), GHTF guidance 154
 device classification
 active device decision tree 131, 132
 additional rules 133
 device class and rules 161
 invasive device classification decision tree 129, 130
 IVD device classification 159
 noninvasive classification decision tree 128
 device conformity assessment 117
 device Identifier (DI) 42
 device package, definition 43
 device premarket requirements
 active devices 126
 additional rules 127
 classification rules 122
 conformity assessment principles 117
 declaration of conformity 118–122
 design and manufacturing requirements 115–122
 device definition 114–122
 harmonized conformity assessment procedures 119
 invasive devices 124
 manufacturer/device registration 119
 medical devices classification principles 122

noninvasive devices 123
 Quality Management System (QMS) 118–122
 registration with regulatory authorities 119
 safety and performance requirements 114–122
 standards in medical device assessment 122
 summary technical documentation 118–122
 device registration, IVD devices 165
 diagnostic or measuring function of devices 116
 direct-to-consumer (DTC) advertising and promotion
 prescription drug advertising 19

E

Economic Community of West African States (ECOWAS)
 membership 6
 Egypt, pricing of medical services 93
 energy source connection for devices 116
 England
 HTA programs/bodies in 87
 process map for 90
 environmental standards, IVDs 166–181
 essential health service package (EHSP) 94
 essential principles, device safety and performance 114
 Ethical Analysis (ETH) 83
 Ethiopia, EHSP implementation 94
 EUDAMED
 device lifecycle information 49
 EU-level Transparency Committee 61
 EUnetHTA 83
 Eurasia, implementation of harmonization in 4
 Eurasian Economic Union (EAEU/EEU), harmonization 5
 European Collaboration on Health Technology Assessment
 (ECHTA) 82
 European Commission (EC)
 HTA studies 82
 ICH Q7 adoption 15
 initiatives on pricing and reimbursement 61
 medicinal price/reimbursement controls legal framework
 60–77
 software as medical device 197
 Transparency Directive update 60
 European Conformity (CE) Mark
 for software 202
 postmarket surveillance system requirements 210
 European Falsified Medicines Directive (FMD)
 aims and scope of 44–55
 requirements 44–55
 European Medicines Agency (EMA)
 post inspection certificates 24–27

- product quality defect reporting 25
- European Network for Health Technology Assessment (EUnetHTA) Project 82
- European Union (EU)
 - AIMD requirements 189
 - combination products 229–234
 - EUDAMED 49–58
 - European Falsified Medicines Directive 44–58
 - EU Unique Device Identifier (UDI) System 48–58
 - HTA development in 82
 - inspection process 22–27
 - In Vitro Diagnostic Medical Device Regulation 167
 - ISO 13485 compliance 154–156
 - medical device software requirements 204
 - postmarket surveillance system 210
 - pricing and reimbursement 59, 59–77
 - pricing and reimbursement models used in 62–77
 - pricing and reimbursement policies 59–60
 - software classification 200–207
 - software regulation 197–207
 - VICH program 4
- EU Unique Device Identifier (UDI) System
 - aims and scope of 48–55
 - Basic EU UDI-DI definition 49
 - implementation timeline 50–55
 - implications and challenges 50–55
 - labeling requirements 49–55
 - requirements and implementation 49–55
- evidence-based guidance, NICE use of 87
- evidence-based international standards 7

F

- Falsified Medicines Directive (FMD)
 - implementation 46–55
 - implications and challenges 47–55
 - supply chain stakeholder requirements 45
 - third countries 48
 - timeline for implementation 47–55
- FDA-accredited issuing agency (IA) 42
- Federal Trade Commission (FTC), false claim regulation 20
- Field Safety Corrective Action (FSCA), reasons for 214
- field safety notices (FSNs), content and actions required 215–217
- foods, dietary supplements, and cosmetics, regulatory
 - history and requirements 3
- France
 - healthcare delivery and funding 67
 - HTA comparison with EU countries 92

G

- Germany
 - healthcare delivery and funding 69
 - HTA comparison with EU and UK 92
 - process map for 86
- global atlas of medical devices 2
- Global Harmonization Task Force (GHTF)
 - device classification principles 161
 - history 4
 - QMS guidance 154
 - submission structure 187
- Global UDI Database (GUDID) 42
- good clinical practice (GCP)
 - compliance and 14–27
- good distribution practice (GDP)
 - certificates for 18
 - requirements for 17–27
- good documentation practices (GDocP) 18–27
- good laboratory practices (GLP)
 - scope of nonclinical studies 13–27
- good manufacturing practice (GMP) 226
 - combination products (US) 226
 - definition and scope of 15–27
- good pharmacovigilance practices (GPvP) 18, 18–27
- GS1 Global Location Number (GLN) 53
- GS1 Healthcare Reference Guide 53
- Gulf States/Region
 - HTA implementation 93

H

- harmonization
 - ASEAN PPWG 5
 - device conformity assessment procedures 119
 - EU HTA 87–91
 - Eurasian Economic Union (EAEU/EEU) 5
 - history of 3
 - ICH Q7 for GMP 15
 - IEC 62304 in US and EU 201
 - IMDRF regional initiatives 4
 - of inspection process 23
 - regulatory and payer approval 59
 - unique device identification system 165–181
 - WHO initiatives 7
- Health Canada (HC)
 - pharmacovigilance practices 18
- healthcare products 12
 - counterfeit and regulations 33
 - development process for 12

- healthcare professionals (HCPs)
 - advertising to 20
 - health effects evaluations 65
 - Health Policy Forum (HPF) in MENA 93
 - Health Problem and Current use of Technology (CUR) 83
 - Health Technology Assessment (HTA) 79
 - comparison of EU countries and UK 92
 - definition 79
 - development in EU 82
 - domains within 83
 - economic analysis used in 81
 - health product market access 80
 - history 80–81
 - models used in EU 83
 - organization and structure of HTA Bodies 83–91
 - pricing and reimbursement 63
 - role in decision-making in EU 86–91
 - UK 88
 - UK and EU comparison 90–91
 - use in decision making 80
 - Highly Specialised Technologies (HST) evaluations 74
 - HTA bodies (HTABs) 80
 - HTA Core Model 83
 - human factors
 - combination products 234
 - IEC 62366 standard 234
- I**
- IEC 62366, human factors standard 234
 - import alerts/distribution bans 24
 - India
 - device classification and UDI use 52
 - track-and-trace and barcode for medicines 51–58
 - indirect medical purpose 167
 - infection and microbial contamination risk for devices 115
 - infringement on intellectual property 34
 - INMETRO certification (devices) 20
 - inspections
 - by FDA 22
 - harmonization of 23
 - IVD PMS 164
 - postapproval inspections 21
 - preapproval, by regulatory authority 21
 - Inspectorates Association 23
 - installation qualification (IQ), GHTF guidance 154
 - instructions from manufacturer for device 116
 - integral drug–device combination (iDDC) products 232
 - intellectual property (IP) infringement, during design
 - phase 36
 - intended use
 - “indirect medical purpose” 167
 - in software regulation 196
 - laboratory developed tests 175
 - “lifestyle tests” 167
 - International Coalition of Medicines Regulatory Authorities (ICMRA) membership 6
 - International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) 4
 - International Council for Harmonisation (ICH)
 - history 3
 - ICH Q7 guideline 15
 - pharmacovigilance definition 2
 - TPLC lifecycle 12
 - International Electrotechnical Commission (IEC) 62304,
 - software lifecycle process 201
 - International Generic Drug Regulators Programme (IGDRP), consolidation with IPRF 6
 - International Medical Device Regulators Forum (IMDRF)
 - harmonization 4
 - MDSAP pilot 4
 - National Competent Authority Report (NCAR) Exchange Program 3
 - recommended UDI framework 50
 - Regulated Product Submission program 164
 - software/device definitions 196
 - software guidance 196
 - Table of Contents (ToC) format 21, 136
 - International Network of Agencies for Health Technology Assessment (INAHTA) 80
 - International Organization for Standardization (ISO)
 - guidance for software 196
 - ISO 10993 185–186
 - ISO 13485 12, 149, 154, 152–156, 214
 - ISO 14971 188, 214
 - International Pharmaceutical Regulators Forum (IPRF)
 - consolidation of 6
 - implementation of harmonization 4
 - International Pharmaceutical Regulators Programme (IPRP)
 - history and benefits of 6
 - International Society for Technology Assessment in Health Care (ISTAHC) 80
 - investigational device exemption (IDE)
 - de novo classification 174–181
 - software or firmware 174
 - in vitro diagnostic devices (IVDs) 159
 - Class A device 165
 - Class B device 166

- Class C device 167
- classification principles 160
- classification rules 162, 163
- conformity assessment elements 163
- conformity assessment stages 178
- Declaration of Conformity 164
- definition 160, 169
- device risk class and requirements 161
- GHTF classification system 161
- PMS and vigilance requirements 168
- quality management system 164
- regulatory changes for 168–181
- technical documentation 164–180
- US regulation 169–181
- ISO 10993 standard, protection from biological risk 185–186
- ISO 13485
 - 2016 requirements 150
 - CE marking/certificates of compliance for compliance 154
 - historical perspective 149
 - in regulatory systems 152–156
 - postmarket surveillance for devices 214
 - quality management systems for devices 15
- ISO 14971
 - AIMD risk management 188
 - postmarket surveillance procedures 214
- ISO/IEC 17025 certification 14
- Italy
 - healthcare delivery and funding 72
 - HTA comparison with EU countries 92

J

- Japan
 - drug/device pricing framework 100
 - HTA emphasis in 98
 - HTA pilot evaluation of products 97
 - ICH Q7 adoption 15
 - VICH program 4
- Jordan, HTA implementation in 93

K

- Kenya, HTA implementation 94
- Korea Fair Trade Commission 20

L

- labeling requirements
 - AIMDs 188
 - EU FMD requirements 49
 - under US UDI rule 43

- laboratory developed tests (LDTs)
 - intended use 175
 - risk-based classification 175
- Latin America (LATAM)
 - country-specific HTA overview 104
 - HTA development 100–112
 - HTA timeline in 106
- laws, regulations, and guidance covered
 - active implantable medical devices (AIMDs) 183
 - combination products 219
 - Health Technology Assessment (HTA) 79
 - international counterfeit and regulation 33
 - international harmonization 1
 - in vitro diagnostic devices 159
 - medical device premarket requirements 113
 - medical device quality management systems 147
 - postmarket requirements for devices 209
 - reimbursement and pricing 59
 - software 195
 - technical and regulatory requirements (devices) 135
- lifecycle management (LCM)
 - combination products (EU) 233–234
 - device postmarket surveillance system 210
 - device technical file 216
 - for IVDs 168–181
 - software 201
 - “lifestyle tests” 167

M

- Malaysia
 - HTA adoption in 95–112
- Malaysian Health Technology Assessment Section (MaHTAS) 95
 - 1995–2018 impact 95
 - historical milestones 96
- manufacturing and environmental properties for devices 115
- manufacturing/manufacturer
 - AIMD process validation 188
 - combination products (US) 226–234
 - device design and requirements 115–134
 - IVD device registration 165
 - IVD lifecycle management 168
 - periodic reports from 216
 - quality control requirements in 14
 - reporting requirements for devices 217
 - requirements for compliance 12
- marketing authorization application (MAA)
 - applicability of GxPs 22
 - certificate of compliance 21

- HTA in 80
 - platform iDDCs 232
 - marketing authorization holder (MAH)
 - compliance by 22
 - compliance requirements 12
 - market withdrawal 25
 - mechanical risk protection for devices 116
 - medical device conformity assessment elements, quality
 - management system 147–156
 - medical device data systems (MDDS) 196
 - medical device quality management system (MDQMS) 147
 - conformity assessment requirements 148
 - design and development control steps 152
 - design controls on the design process 153
 - interrelated processes 148
 - ISO 13485 historical perspective 149–156
 - ISO 13485 in regulatory systems 152–156
 - medical device conformity assessment elements 147
 - PDCA methodology 149
 - process validation 154–156
 - QMS vs GMP 148–156
 - medical devices
 - active implantable medical devices 183
 - combination products 219
 - essential principles of safety and performance 114
 - EU risk classification 119
 - GHTF risk classification 119
 - in vitro diagnostic devices 159
 - postmarket requirements 209
 - premarket requirements 113
 - quality management systems 147
 - regulatory history 2
 - regulatory requirements 135
 - safety and efficacy studies for 14
 - technical and regulatory requirements 135
 - US device classification 119
 - Medical Device Single Audit Program (MDSAP) Pilot 4
 - Medicines and Healthcare products Regulatory Agency (MHRA)
 - refusal to grant inspection 24
 - Member States (EU)
 - medicinal product pricing 60
 - postapproval inspection responsibility 21
 - pricing and reimbursement in 59
 - meningitis B vaccine pricing 59
 - Middle East and North Africa (MENA) countries
 - health policy network in 93
 - HTA implementation 91
 - Ministry of Health, Labour and Welfare (MHLW)
 - ICH Q7 adoption 15
 - Multiple Technology Appraisal (MTA) 74
- ## N
- National Competent Authority Report (NCAR)
 - exchange criteria and report format 211–217
 - Exchange Program 3
 - National Coordinating Centre for Health Technology Assessment (NCCHTA) 73
 - National Evidence-based healthcare Collaborating Agency (NECA) 98
 - National Health Insurance (NHI) system (South Korea) 95
 - National Health Service (NHS) 73
 - National Health Service (NHS), NICE as advisory body to 87
 - National Institute for Health and Care Excellence (NICE) 73, 87
 - National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) 54
 - National Insurance (NI) 73
 - National Medical Products Administration (NMPA)
 - ICH Q7 adoption 15
 - UDI device identification rules 54
 - New Zealand
 - prescription drug advertising 19
 - nonclinical studies
 - pharmaceutical/medicinal products 14
 - North America
 - HTA development in 99–112
 - Northern Ireland, HTA use in 87
 - notified body opinion (NBOp) 232
- ## O
- off-the-shelf (OTS) software, guidance on use 199
 - oncology products, EMA authorization and HTA decision 89
 - operational qualification (OQ), GHTF guidance 154
 - Organisational Aspects (ORG) 83
 - Organisation for Economic Co-operation and Development (OECD)
 - evidence-based international standards 7
 - Organisation of Islamic Cooperation (OIC), membership 7
 - outsourcing of software 202
 - over-the-counter (OTC) products
 - advertising of 19
- ## P
- Pan American Health Organization (PAHO)
 - IMDRF status 4

- Pan-American Network on Drug Regulatory Harmonization (PANDRH)
 - regulatory authority membership 5
- Patient-Centered Outcomes Research Initiative (PCORI) 99
- Patients and Social Aspects (SOC) 83
- performance and clinical evaluation 117
- Pharmaceutical Inspection Co-operation Scheme (PIC/S)
 - history 3
- Pharmaceutical Inspection Cooperation Scheme (PIC/S)
 - compliance requirements 15–27
 - GMP inspections 23
- pharmaceutical products
 - regulatory history of drugs 2
- Pharmaceuticals and Medical Devices Agency (PMDA)
 - HTA in reimbursement prices 98
 - ICH Q7 adoption 15
- pharmacovigilance
 - elements of 2
 - WHO definition 2
- postmarket requirements (devices) 209
 - combination products (US) 227
 - criteria for competent authority reporting 212
 - distribution records for traceability 211
 - FSCA and CAPA plans 214–217
 - periodic reports 216
 - postmarket surveillance activities 214–217
 - vigilance reporting in PSSS 210–217
- postmarket surveillance system (PMSS), devices in EU 210
- postmarket surveillance/vigilance system (PMS)
 - combination products (EU) 233–234
 - for IVDs 164
- premarket approval application (PMA)
 - AIMDs 190
 - IVDs 173
- premarketing authorization (PMA) holders
 - compliance by 22
- Premarket Notifications (510(k), IVDs) 173
- premarket requirements
 - medical devices 113
- pricing and reimbursement
 - competent authorities 74
 - cost-based (CbP) model 62
 - current trends 66
 - economic evaluations of treatments 64
 - EU pricing and reimbursements 62–77
 - European Union 59
 - health effects measurement 65
 - HTA-models case studies 66–78
 - reference-based pricing model 62

- value-based pricing model 62
- primary mode of action (PMOA) 221
- primary subject matter expert (SME) 25
- process validation
 - biological safety 141
 - components of 154
 - decision tree for 154
 - steps involved 154
- process validation (device QMS)
 - facility and equipment validation 155–156
 - process validation decision tree 155
 - supplier control 157
 - Validation Master Plan (VMP) 155
- production Identifier (PI) 42
- product manufacturers (510(k), compliance) 22
- protection against radiation from devices 116

Q

- Quality-Adjusted Life Year (QALY) 65, 89
- Quality Management System for devices (MDQMS),
 - conformity assessment element 147
- quality management system (QMS)
 - demonstration of supplier control 156
 - device premarket requirements 118–122
 - inspections of 21
 - medical devices 147
 - product/services from suppliers 156

R

- recalls 25
- reference-based pricing model 62
- Regulated Product Submission (RPS)
 - device harmonization initiative 136
 - format for IVD/non-IVD 142
 - IMDRF program 164
- regulations
 - globalization effects on 7
- regulators' role, statements of responsibility 2
- regulatory affairs
 - history of 1
- Regulatory Harmonization Steering Committee (RHSC) 5
- regulatory professional, role of
 - communication with regulators 25
 - inspection support 26–27
 - professional ethics 26
 - system owner and SME 25–27
- risk assessment/management
 - analysis for AIMDs 188

S

Safety (SAF) 83
 Saudi Arabia
 HTA for high-cost drugs 91
 Scotland 89
 HTA programs/bodies in 87
 process map for 91
 Scottish Health Technologies Group (SHTG) 87
 Scottish Medicines Consortium (SMC) 87
 self-testing devices, intended use 160
 self-testing or self administration device risks 116
 software 195
 as device vs. standalone 196
 as regulated medical device 196–207
 categories and classification 200–207
 decision tree for EU MDR 198
 development of 201–207
 FDA precertification program 203
 in IVDs 174
 personal health data protection 203–207
 quality management system 202
 types and EU qualification 205
 software as a medical device (SaMD), definition/
 characteristics 196
 South Africa
 HTA implementation 94
 South Korea
 barcode or RFID tag for medicines 53–58
 HTA flow diagram 98
 HTA introduction in 95–112
 National Evidence-based healthcare Collaborating
 Agency (NECA) 98
 UDI framework for devices 53
 Spain
 healthcare delivery and funding 71
 HTA comparison with EU countries 92
 standard operating procedures (SOPs)
 equipment and process validation 155
 equipment related 155
 process-related 156
 sterilization validation 141
 stock recovery 25
 Sub-Saharan African countries, HTA implementation 91, 93
 sulfathiazole tablets 15
 Summary Technical Documentation (STED) guidance
 118, 136
 supplied energy or substance risks 116
 Sweden, value-based pricing in 66

Swedish Council on Technology Assessment in Health
 Care 82
 system owner 25

T

Table of Contents (ToC) format 21, 136
 clinical evidence (Chapter 4) 142–144
 harmonization for IVD submissions 164
 labeling and promotional material (Chapter 5) 142–144
 non-clinical evidence (Chapter 3) 140–144
 regional administrative (Chapter 1) 138–144
 submission context (Chapter 2) 139–144
 technical and regulatory requirements for devices
 corrective and preventive actions 143
 design and development and planning 143–144
 essential technical file elements 136–144
 GHTF submission guidance by device class 137
 outsourcing 143
 postmarket use of STED 138
 risk management principles 143–144
 RPS documentation/ToC requirements 137–144
 RPS format 142
 use of standards 142–144
 verification and validation 140
 technical file/design dossier elements
 postmarket phase 136
 premarket phase 136
 submission before market entry 136
 technology appraisal (TA) committees (NICE) 87
 technology assessment in HTA 80
 thalidomide 15
 The Americas
 harmonization organizations in 5–7
 HTA implementation in North America 99–112
 ToC Chapter 1
 Declaration of Conformity 139
 topics covered 138–145
 ToC Chapter 2
 device description 139–145
 global market history 139
 indications/intended use 139
 similar/previous device generations 139
 ToC Chapter 3
 animal studies for device conformity 141
 biological safety 141
 Essential Principles checklist 140
 materials biocompatibility 141
 medicinal substances in device 141
 product verification and validation 140

- risk management 140
- software verification and validation 141
- sterilization validation 141
- ToC Chapter 4, clinical evidence of EP conformity 142
- ToC Chapter 5, labeling and promotional material 142
- total product lifecycle (TPLC) approach/methodology 12
 - vigilance in 18
- Tunisia, HTA implementation 93
- Turkey
 - serialization of medicines in 54–58
 - UDI-like system for devices 54

U

- unique device/drug identification (UDI)
 - global harmonization 165
 - IMDRF guidance on 50
 - in prevention of counterfeit/falsification 36
- United Kingdom (UK) 23
 - EU-UK Trade and Cooperation Agreement 61
 - healthcare delivery and funding 73–77
 - HTA comparison with EU countries 92
 - HTA programs in 87–91
 - Joint Committee on Vaccination and Immunisation (JCVI) 59
 - surveillance approach in 23
 - value-based pricing 66
- United States (US)
 - AIMD requirements 190–194
 - combination products 222–234
 - false claim regulation 20
 - HTA implementation 99–112
 - “HTA-like bodies” 102
 - IVD regulations 169–181
 - prescription drug advertising 19
 - QSR for quality management 153–156
 - recalls, classification of 25
 - software regulation 197
 - VICH program 4
- United States (US) medical device reporting
 - importers 217
 - legal framework 217
 - user facilities requirements 217
- unregulated software 200
- US Drug Supply Chain Security Act (DSCSA) 36
 - aims and scope of 36–58
 - dispensers’ implementation of 39–58
 - implentation for dispensers 39–58
 - implications and challenges of 41
 - terminology and stakeholders definitions 38

- US Food and Drug Administration (FDA)
 - civilmoney penalties for noncompliance 24
 - commercialization/post commercialization regulation 21–27
 - devarment 24
 - ICH Q7 adoption 15
 - medical device GMPs 15
 - oversight of IVDs 169
 - post inspection observations 23
 - Postmarket Surveillance Studies Program 214
 - QSR and ISO 13485 152
 - software classification revision 199–200
 - software precertification program 203
 - timelinecounterfeit and regulation implementation 40
 - Warning Letters 24
- US IVD regulation
 - Class I (general controls) 170–181
 - Class III (premarket approval) 171–181
 - Class II (special controls) 171–181
 - CLIA categorization 171–181
 - cybersecurity with 175
 - definitions 169–181
 - investigational device exemption 174–181
 - oversight of 169
 - postmarket surveillance 175
 - premarket submission types 173–181
 - presubmission program 172–181
 - risk-based classification 170
- US Unique Device Identifier (UDI) System Rule
 - aims and scope of 42–55
 - definition and requirements for 42–55
 - implementation and implications of 43
 - requirements and implementation 42–55

V

- validation, facility and equipment 155
- Validation Master Plan (VMP) 155
- value-based pricing model 62
- Vanessa’s Law 18
- verification and validation
 - AIMD submissions 188
 - device software 141
 - device sterilization 141
 - documentation for devices 140
- veterinary medicinal products
 - regulatory history 3

W

- Wales, HTA use in 87
- willingness-to-pay threshold 65

- World Health Organization (WHO)
 - advertising and promotion recommendations 19
 - counterfeit products 34
 - country and regional offices of 6
 - data and record management 19
 - global atlas of medical devices 2
 - Global Surveillance and Monitoring System 50
- good manufacturing practices draft 15
- health technology definition 79
- HTA definition 63
- IMDRF status 4
- pharmacovigilance definition 2
- price transparency on vaccines 60

EU

US

INTERNATIONAL